Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03711578
Title Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Rhizen Pharmaceuticals SA
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
Clearview Cancer Institute Huntsville Alabama 35805 United States Details
Colorado Blood Cancer Institute Denver Colorado 80218 United States Details
Florida cancer specialists & Research Institute Florida City Florida 33401 United States Details
Florida Cancer Specialist/ South Fort Myers Florida 33908 United States Details
Florida Cancer Specialists/North Saint Petersburg Florida 33705 United States Details
HCA Midwest Health Kansas City Kansas City Missouri 64132 United States Details
Tennessee Oncology Chattanooga Tennessee 37404 United States Details
Tennessee Oncology Nashville Tennessee 37203 United States Details
Blacktown Hospital, Blacktown Cancer and Haematology Center Blacktown New South Wales 2148 Australia Details
Brisbane Clinic for Lymphoma, Myeloma and Leukaemia, Greenslopes, Queensland 4120 Australia Details
John Flynn Private Hospital, Tugun Queensland 4224 Australia Details
Royal Adelaide Hospital Adelaide South Australia 5000 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field